- Home
- HAFN vs LGND Comparison
HAFN vs LGND Comparison
Compare HAFN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- LGND
- Stock Information
- Founded
- HAFN 2012
- LGND 1987
- Country
- HAFN Singapore
- LGND United States
- Employees
- HAFN N/A
- LGND 68
- Industry
- HAFN
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- HAFN
- LGND Health Care
- Exchange
- HAFN Nasdaq
- LGND Nasdaq
- Market Cap
- HAFN 2.7B
- LGND 2.2B
- IPO Year
- HAFN N/A
- LGND 1992
- Fundamental
- Price
- HAFN $5.99
- LGND $159.08
- Analyst Decision
- HAFN Strong Buy
- LGND Strong Buy
- Analyst Count
- HAFN 1
- LGND 8
- Target Price
- HAFN $6.50
- LGND $144.71
- AVG Volume (30 Days)
- HAFN 1.3M
- LGND 139.7K
- Earning Date
- HAFN 08-27-2025
- LGND 08-05-2025
- Dividend Yield
- HAFN 15.29%
- LGND N/A
- EPS Growth
- HAFN N/A
- LGND N/A
- EPS
- HAFN 1.20
- LGND N/A
- Revenue
- HAFN $2,631,664,000.00
- LGND $181,488,000.00
- Revenue This Year
- HAFN N/A
- LGND $18.41
- Revenue Next Year
- HAFN $1.07
- LGND $18.87
- P/E Ratio
- HAFN $4.97
- LGND N/A
- Revenue Growth
- HAFN N/A
- LGND 53.40
- 52 Week Low
- HAFN $3.61
- LGND $81.74
- 52 Week High
- HAFN $8.26
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- HAFN 67.56
- LGND 71.61
- Support Level
- HAFN $5.33
- LGND $149.51
- Resistance Level
- HAFN $5.60
- LGND $155.28
- Average True Range (ATR)
- HAFN 0.14
- LGND 6.09
- MACD
- HAFN 0.03
- LGND 0.39
- Stochastic Oscillator
- HAFN 98.57
- LGND 90.41
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.